MRNA - Moderna, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.07
+0.17 (+0.95%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close17.90
Open18.14
Bid18.08 x 800
Ask18.45 x 1100
Day's Range17.76 - 18.38
52 Week Range11.54 - 29.79
Volume25,237,508
Avg. Volume2,214,788
Market Cap5.966B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire

    Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive data in the first analysis of safety and activity in its Phase 1 study evaluating escalating doses of mRNA-1944 administered via intravenous infusion in healthy adults. At all three dose levels, the administration of mRNA-1944 led to detectable levels of CHKV-24 antibody in all participants, ranging from 1 µg/mL to 14 µg/mL.

  • Business Wire

    Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive data from the three-month interim analysis of safety and immunogenicity of the Phase 1 study of its investigational cytomegalovirus (CMV) vaccine (mRNA-1647).

  • Business Wire

    Moderna Appoints Tracey Franklin as Chief Human Resources Officer

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tracey Franklin has been appointed Chief Human Resources Officer.

  • Business Wire

    Moderna to Host R&D Day on September 12, 2019

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its third annual R&D Day for analysts and investors at 8:00 a.m. ET on Thursday, September 12 at the JW Marriott Essex House in New York City. Moderna’s R&D Day will include presentations from Stéphane Bancel, chief executive officer, Tal Zaks M.D., Ph.D., chief medical officer and key opinion leaders with a focus on the Company’s clinical development pipeline.

  • Business Wire

    Moderna to Present at Upcoming Investor Conferences

    A replay of each webcast will be archived on Moderna’s website for 30 days following the presentations. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

  • Business Wire

    Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the prevention of Zika virus infection in healthy adults. Fast Track is designed to facilitate the development and expedite the review of therapies and vaccines for serious conditions and fill an unmet medical need.

  • Business Wire

    Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results

    Phase 2 Personalized Cancer Vaccine study initiated, with first patient consented

  • Business Wire

    Moderna to Present at BMO 2019 Prescriptions for Success Healthcare Conference

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Pamela Cohen, M.D., Head, Clinical Oncology Development, will present at the BMO 2019 Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 at 3:20 p.m. ET. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

  • Business Wire

    Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Stephane Bancel, Chief Executive Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019 at 2:00 p.m. PT (5:00 p.m. ET). A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.

  • Business Wire

    Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at 2019 ASCO Annual Meeting

    Moderna, Inc., (MRNA) a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced interim data from an ongoing Phase 1 clinical study in patients with both resected (adjuvant) and unresected (advanced) solid tumors. The data showed that the Company’s mRNA personalized cancer vaccine (PCV) mRNA-4157, given alone or in combination with Merck’s pembrolizumab (KEYTRUDA®), was well-tolerated at all doses tested and elicited neoantigen-specific T-cell responses.

  • Business Wire

    Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of preclinical data in Science Immunology, showing that mRNA encoding a human monoclonal antibody against the chikungunya virus delivered in a proprietary lipid nanoparticle (LNP) can protect from infection by the virus in vivo.

  • Business Wire

    Moderna Reports First Quarter 2019 Financial Results and Provides Business Updates

    Rare Diseases: New development candidate announced for glycogen storage disease type 1a , a rare metabolic disorder; Company now has five rare disease programs in its pipeli

  • Business Wire

    Moderna to Present at Bank of America Merrill Lynch 2019 Health Care Conference

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tal Zaks, M.D., Ph.D., Chief Medical Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019 at 9:20 a.m. PT (12:20 p.m. ET). A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.

  • Business Wire

    Moderna to Present Preclinical Data at 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

    The Company and academic collaborators to share data from seven preclinical studies demonstrating the potential of mRNA-based therapies to treat rare metabolic and genetic disorder

  • Business Wire

    Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its annual Science Day for analysts and investors on Tuesday, May 7, 2019 at 8:00 a.m. ET in Cambridge, MA. Moderna also announced that it will report its first quarter 2019 financial results before the market opens on Wednesday, May 8, 2019 and, subsequently, host a conference call to discuss these results and provide a corporate update. Moderna’s Science Day will feature presentations from Stephen Hoge M.D., president and Melissa Moore Ph.D., chief scientific officer of Moderna’s mRNA Research Platform with a focus on the Company’s newest advances from its commitment to basic and applied sciences.

  • Business Wire

    Moderna to Present at 18th Annual Needham Healthcare Conference

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tal Zaks, M.D., Ph.D., Moderna’s Chief Medical Officer, will participate in a fireside chat at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 11:20 a.m. ET. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.

  • Business Wire

    Moderna Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights Recent Pipeline Progress

    Shows Continued Execution Across its Pipeline of Infectious Disease, Immuno-Oncology and Rare Disease Programs

  • Business Wire

    Moderna to Present at Upcoming Investor Conferences in March

    A replay of each webcast will be archived on Moderna’s website for 30 days following the presentations. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

  • Business Wire

    Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, March 6, 2019 to report its fourth quarter and full year 2018 financial results and provide a corporate update. The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for 30 days following the call. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

  • Business Wire

    Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of a Phase 1a/b study in Nature Communications showing the potential of mRNA encoding for vascular endothelial growth factor A (VEGF-A) as a regenerative therapeutic. This approach aims to stimulate the growth of new blood vessels, also known as angiogenesis, to improve blood flow in tissues where it is otherwise restricted.

  • Business Wire

    Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced topline data from the first planned interim analysis of safety and immunogenicity from its Phase 1 study of mRNA-1653 in healthy adults.

  • Business Wire

    Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial

    Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the dosing of the first subject in a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944 via intravenous infusion in healthy adults. This is the first monoclonal antibody encoded by mRNA to be dosed in a human and the first development candidate from the Company’s systemic therapeutics modalities to start clinical testing.